Filing summary
Important entity discrepancy: The supplied filing is Bioptix, Inc.’s Form 10-Q for the quarter ended June 30, 2017, not a filing identified as Riot Platforms, Inc. Investors should confirm the filing and issuer before relying on this summary.
Business context and reporting period
The filing reports second-quarter and first-half 2017 results. Bioptix had adopted a plan to exit its subsidiary BiOptix Diagnostics, Inc. (BDI), and classified BDI’s results as discontinued operations. The company described strategic options that included monetizing, partnering, or licensing assets, including its appendicitis product portfolio.
Financial results and liquidity
- Revenue: Continuing-operations license-fee revenue was $24,174 for the quarter and $48,349 for the six months, unchanged from the comparable 2016 periods. Discontinued BDI sales were $17,000 for the quarter and $30,000 for the six months.
- Profit and expenses: Second-quarter net loss was $1.312 million, versus $836,000 in 2016; first-half net loss was $5.666 million, versus $276,000. First-half continuing-operations loss was $2.071 million. The first-half discontinued-operations loss of $3.595 million included $2.754 million of impairment charges. No income tax benefit was recorded.
- Operating costs: First-half selling, general and administrative expense rose 13% to $2.097 million; research and development expense fell 90% to $45,350 as prior product development and commercialization activities wound down. The filing provides no meaningful consolidated margin trend given minimal continuing revenue and the discontinued business.
- Cash flow: First-half net cash used in operations was $2.576 million, including $1.687 million from continuing operations and $889,000 from discontinued operations. Investing activities provided $7.498 million, primarily from selling short-term investments; financing activities provided $1.482 million. Cash increased to $11.934 million.
- Liquidity and balance sheet: At June 30, cash was $11.934 million, working capital $11.137 million, total assets $12.907 million, total liabilities $1.894 million, and stockholders’ equity $11.013 million. Accumulated deficit was $115.521 million. The company reported no current notes and other obligations at quarter-end.
Material changes and unusual items
- BDI’s exit drove discontinued-operation losses and impairment of inventory, equipment, intangible assets, and goodwill. BDI had no inventory or noncurrent assets remaining on the June 30 balance sheet.
- In March, Bioptix completed a $2.25 million common-stock-unit placement, issuing 900,000 shares and 900,000 warrants. A separate $4.75 million convertible-note financing remained in escrow pending release conditions outside the company’s control; the notes carried 2% interest and potential conversion and warrant-related dilution. The filing accrued approximately $27,600 of interest.
- First-half results are not directly comparable with 2016: the prior-year period included a $1.920 million gain on sale of the company’s headquarters, while 2017 included BDI’s discontinued-operation losses and impairment.
- Bioptix paid $299,500 to terminate certain equity rights and recorded an approximately $135,000 gain from cancellation of escrowed shares associated with the BDI acquisition.
Outlook, risks, and contingencies
Management expected near-term operating losses, potentially significant, including costs to exit BDI and public-company and administrative expenses. It believed working capital would cover estimated cash needs for at least a year and a day from the filing, while continuing to monitor spending and explore financing and strategic alternatives. It cautioned that additional financing might not be available on acceptable terms, if at all, and that exit costs could continue. The filing states there were no legal proceedings expected to have a material adverse effect and no material changes to previously disclosed risk factors. A Nasdaq audit-committee composition deficiency identified in April was addressed by a May director appointment.
Investor verification points
- Confirm the issuer identity: the supplied document names Bioptix, Inc., not Riot Platforms, Inc.
- Verify whether the $4.75 million convertible-note proceeds and related securities were released from escrow, and assess resulting dilution and financing obligations.
- Review cash burn, remaining BDI exit costs, and the assumptions behind management’s stated liquidity runway.
- Assess the remaining value and monetization prospects of the company’s assets and licenses, including any termination rights and milestone or royalty conditions.
- Reconcile first-half comparisons with the 2016 headquarters-sale gain and 2017 BDI impairment and discontinued-operation charges.